en · de · es · pt
tirzepatide-notes.peptides1126.com › Wiki › Background And Molecular Development — Background and Details

Background And Molecular Development — Background and Details

By Editorial Desk · published 2025-07-10 · last reviewed 2025-08-29 · Wiki

有关物质 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-08-29. Anything still debated is marked as such rather than presented as settled.

Background and Molecular Development

Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.

Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.

Tirzepatide Pharmacology and Development History

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Tirzepatide at a glance

PropertyValueNotes
Molecular classSynthetic peptideDual incretin receptor agonist
Amino acid count39 residuesIncludes non-natural residues
Approximate mass4.8 kDaReported values vary slightly by source
Fatty acid componentC20 diacidSupports albumin binding
First US approval2022Glycemic indication, weight management followed

Analytical Characterization and Storage

Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.

Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.

Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.

Related pages on this site

储存处理与检测方法

定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测,利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定,常采用液相色谱串联质谱,并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用,但可能受到结构相关肽的交叉反应干扰。

纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息:前者反映疏水性杂质,后者反映聚集体,质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异,属于需要逐案验证的问题。

质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持,单次测定不足以判定批次的稳定性。实验室之间方法转移时,色谱柱品牌与梯度差异常导致保留时间漂移,因此方法验证十分必要。

Analytical Characterization and Storage Stability

Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.

Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.

Dual Incretin Receptor Agonism

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.

Supporting material

=== Stability of naturally occurring nuclides === Most naturally occurring nuclides on earth are beta stable. Nuclides that are not beta stable have half-lives ranging from under a second to periods of time significantly greater than the age of the universe. One common example of a long-lived isotope is the odd-proton odd-neutron nuclide 4019K, which undergoes all three types of beta decay (β−, β+ and electron capture) with a half-life of 1.248×109 years.

== Breast == Breast cancer Ductal carcinoma in situ Inflammatory breast cancer Invasive ductal carcinoma Invasive lobular carcinoma Tubular carcinoma Invasive cribriform carcinoma of the breast (also termed invasive cribriform carcinoma) Medullary carcinoma Male breast cancer Phyllodes tumor Mammary secretory carcinoma Mucinous carcinoma of the breast Papillary carcinomas of the breast

Aerobic exercise § History Bodybuilding § History Exercise § History Exercise physiology § History Exercise trends Fitness boot camp § History Fitness culture Outdoor fitness § History Physical culture

== References == Dean, Adam, and Jonathan Obert. "Rewarded by Friends and Punished by Enemies: The CIO and the Taft-Hartley Act." Labor 18.3 (2021): 78-113. McCann, Irving G. Why the Taft-Hartley Law? New York: Committee for Constitutional Government, 1950. Millis, Harry A. and Brown, Emily Clark. From the Wagner Act to Taft-Hartley: A Study of National Labor Policy and Labor Relations. Chicago: University of Chicago Press, 1950.

== Taxonomy and evolution == The family name Formicidae is derived from the Latin formīca ("ant") from which the words in other Romance languages, such as the Portuguese formiga, Italian formica, Spanish hormiga, Romanian furnică, and French fourmi are derived. The family belongs to the order Hymenoptera, which also includes sawflies, bees, and wasps. Ants evolved from a lineage within the stinging wasps, and a 2013 study suggests that they are a sister group of the Apoidea. However, since Apoidea is a superfamily, ants must be upgraded to the same rank. A more detailed basic taxonomy was proposed in 2020. Three species of the extinct mid-Cretaceous genera Camelomecia and Camelosphecia were placed outside of the Formicidae, in a separate clade within the general superfamily Formicoidea, which, together with Apoidea, forms the higher-ranking group Formicapoidina. Fernández et al. (2021) suggest that the common ancestors of ants and apoids within the Formicapoidina probably existed as early as in the end of the Jurassic period, before divergence in the Cretaceous.

Sources: en.wikipedia.org

Supporting material

=== Helmut Schmidt === Finance Minister Helmut Schmidt (SPD) formed a coalition and he served as Chancellor from 1974 to 1982. Hans-Dietrich Genscher, a leading FDP official, became Vice-Chancellor and Foreign Minister. Schmidt, a strong supporter of the European Community (EC) and the Atlantic alliance, emphasised his commitment to "the political unification of Europe in partnership with the USA". Mounting external problems forced Schmidt to concentrate on foreign policy and limited the domestic reforms that he could carry out. The USSR upgraded its intermediate-range missiles, which Schmidt complained was an unacceptable threat to the balance of nuclear power, because it increased the likelihood of political coercion and required a western response. NATO responded in the form of its twin-track policy. The domestic reverberations were serious inside the SPD, and undermined its coalition with the FDP. One of his major successes, in collaboration with French President Valéry Giscard d'Estaing, was the launching of the European Monetary System (EMS) in April 1978.

==== MeSH D12.776.664.962.500 – ribonucleoproteins ==== MeSH D12.776.664.962.500.500 – heterogeneous-nuclear ribonucleoproteins MeSH D12.776.664.962.500.500.061 – RNA-binding protein FUS MeSH D12.776.664.962.500.500.100 – heterogeneous-nuclear ribonucleoprotein group a-b MeSH D12.776.664.962.500.500.200 – heterogeneous-nuclear ribonucleoprotein group c MeSH D12.776.664.962.500.500.300 – heterogeneous-nuclear ribonucleoprotein d MeSH D12.776.664.962.500.500.400 – heterogeneous-nuclear ribonucleoprotein group f-h MeSH D12.776.664.962.500.500.500 – heterogeneous-nuclear ribonucleoprotein k MeSH D12.776.664.962.500.500.600 – heterogeneous-nuclear ribonucleoprotein l MeSH D12.776.664.962.500.500.700 – heterogeneous-nuclear ribonucleoprotein group m MeSH D12.776.664.962.500.500.800 – heterogeneous-nuclear ribonucleoprotein u MeSH D12.776.664.962.500.500.900 – RNA-binding protein EWS MeSH D12.776.664.962.500.625 – ribonuclease p MeSH D12.776.664.962.500.750 – ribonucleoproteins, small cytoplasmic MeSH D12.776.664.962.500.750.800 – signal recognition particle MeSH D12.776.664.962.500.875 – ribonucleoproteins, small nuclear MeSH D12.776.664.962.500.875.590 – ribonucleoproteins, small nucleolar MeSH D12.776.664.962.500.875.600 – ribonucleoprotein, u1 small nuclear MeSH D12.776.664.962.500.875.605 – ribonucleoprotein, u2 small nuclear MeSH D12.776.664.962.500.875.615 – ribonucleoprotein, u4-u6 small nuclear MeSH D12.776.664.962.500.875.620 – ribonucleoprotein, u5 small nuclear MeSH D12.776.664.962.500.875.625 – ribonucleoprotein, u7 small nuclear MeSH D12.776.664.962.500.906 – RNA-induced silencing complex MeSH D12.776.664.962.500.937 – vault ribonucleoprotein particles

Piracetam is not a vitamin, mineral, amino acid, herb or other botanical, or dietary substance for use by humans to supplement the diet by increasing the total dietary intake. Further, piracetam is not a concentrate, metabolite, constituent, extract or combination of any such dietary ingredient. [...] Accordingly, these products are drugs, under section 201(g)(1)(C) of the Act, 21 U.S.C. § 321(g)(1)(C), because they are not foods and they are intended to affect the structure or any function of the body. Moreover, these products are new drugs as defined by section 201(p) of the Act, 21 U.S.C. § 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.

===== Fifth generation ===== Since the mid-1990s, the fifth generation of silicone-gel breast implant is made of a high-strength, highly cohesive silicone gel that mostly eliminates the occurrences of filler leakage ("silicone gel bleed") and of the migration of the silicone filler from the implant pocket to elsewhere in the woman's body. These implants are commonly referred to as "gummy bear breast implants" for their firm, pliant consistency, which is similar to gummy candies. The studies Experience with Anatomical Soft Cohesive Silicone gel Prosthesis in Cosmetic and Reconstructive Breast Implant Surgery (2004) and Cohesive Silicone gel Breast Implants in Aesthetic and Reconstructive Breast Surgery (2005) reported low incidence-rates of capsular contracture and of device-shell rupture; and greater rates of improved medical-safety and technical-efficacy than that of early generation breast implant devices.

== Other antibody binding proteins == In addition to protein A/G, other immunoglobulin-binding bacterial proteins such as protein A, protein G and protein L are all commonly used to purify, immobilize or detect immunoglobulins. Each of these immunoglobulin-binding proteins has a different antibody binding profile in terms of the portion of the antibody that is recognized and the species and type of antibodies.

Sources: en.wikipedia.org

Frequently asked questions

What receptor targets does tirzepatide engage?

It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.

When did regulatory approval occur?

United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.

How does the molecule differ from native incretin hormones?

Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.

What receptors does tirzepatide target?

It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.

Network